Tumor necrosis factor-α as a potential target in the treatment of systemic lupus erythematosus: A role for the HMG-CoA reductase inhibitor simvastatin [3]

Journal of Rheumatology

Volumn 33, Issue 11, 2006, Pages 2361-2363

  Kotyla, Przemyslaw J ^a   Sliwinska Kotyla, Bogna ^a   Kucharz, Eugene J ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCYTE CHEMOTACTIC PROTEIN 1; SIMVASTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; AUTOIMMUNITY; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMAN; LETTER; PLEIOTROPY; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ATHEROSCLEROSIS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33751019456     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (9)

1. Shovman O, Gilburd B, Shoenfeld Y. The role of inflammatory cytokines in the pathogenesis of systemic lupus erythematosus-related atherosclerosis: a novel target for treatment? J Rheumatol 2006;33:445-7.
2. Urowitz MB, Bookman AAM, Kocher BE, et al. The bimodal mortality in SLE. Am J Med 1976;60:221-5.
3. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-9.
4. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with up-regulation of the tumor necrosis factor/tumor necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003;48:2533-40.
5. Scuderi F, Convertino R, Molino N, et al. Effect of pro-inflammatory/ anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. Autoimmunity 2003;36:71-7.
6. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
7. Yokota K, Miyazaki T, Hirano M, Akiyama Y, Mitura T. Simvastatin inhibits production of interleukin 6 (IL-6) and IL-8 and cell proliferation induced by tumor necrosis factor alpha in fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Rheumatol 2006;33:463-71.
8. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic disease: a preliminary study. Lupus 2003;12:607-11.
9. McFarlane SI, Muniyappa R, Francisco R, Sowers JR. Pleiotropic effects of statins: Lipid reduction and beyond. J Clin Endocrinol Metab 2002;87:1451-8.